Takeda's adzynma (adamts13, recombinant-krhn) approved by u.s. fda as the first and only recombinant adamts13 enzyme replacement therapy for the treatment of congenital thrombotic thrombocytopenic purpura (cttp)

Osaka, japan & cambridge, mass.--(business wire)--takeda (tse:4502/nyse:tak) today announced that the u.s. food and drug administration (fda) has approved adzynma (adamts13, recombinant-krhn) for the prophylactic and on-demand treatment of adult and pediatric patients with congenital thrombotic thrombocytopenic purpura (cttp). adzynma is the first and only fda-approved recombinant adamts13 (radamts13) protein designed to address an unmet medical need in people with cttp by replacing the deficie.
TAK Ratings Summary
TAK Quant Ranking